Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 675 of 2529 entries
View as:

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Phase: N/A Priority: Normal
NCT ID: NCT01890746 Org: User:
Start: 09/05/13 End: 01/25/17 Due: 01/25/18

Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)

Phase: N/A Priority: Normal
NCT ID: NCT00237172 Org: User:
Start: 09/30/02 End: - Due: -

Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)

Phase: N/A Priority: Normal
NCT ID: NCT05089656 Org: User:
Start: 02/01/22 End: 04/29/25 Due: 04/29/26

A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.

Phase: N/A Priority: Normal
NCT ID: NCT01237236 Org: User:
Start: 12/21/10 End: 03/09/17 Due: 03/09/18

A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults

Phase: N/A Priority: Normal
NCT ID: NCT03100058 Org: User:
Start: 05/06/17 End: 08/02/18 Due: 08/02/19

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01958021 Org: User:
Start: 12/17/13 End: 03/16/23 Due: 03/16/24

Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

Phase: N/A Priority: Normal
NCT ID: NCT04072302 Org: User:
Start: 09/15/14 End: 11/29/17 Due: 11/29/18

Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

Phase: N/A Priority: Normal
NCT ID: NCT00093639 Org: User:
Start: 08/31/04 End: 08/31/06 Due: 08/31/07

SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis

Phase: N/A Priority: Normal
NCT ID: NCT03136861 Org: User:
Start: 06/30/17 End: 02/15/19 Due: 02/15/20

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

Phase: N/A Priority: Normal
NCT ID: NCT03623243 Org: User:
Start: 02/14/19 End: 07/06/22 Due: 07/06/23

Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients

Phase: N/A Priority: Normal
NCT ID: NCT01320358 Org: User:
Start: 05/10/11 End: 11/18/11 Due: 11/18/12

Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Phase: N/A Priority: Normal
NCT ID: NCT01535261 Org: User:
Start: 02/29/12 End: 03/31/15 Due: 03/31/16

Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04321252 Org: User:
Start: 07/22/20 End: 11/10/20 Due: 11/10/21

Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT01025817 Org: User:
Start: 01/31/10 End: 03/31/13 Due: 03/31/14

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

Phase: N/A Priority: Normal
NCT ID: NCT00242580 Org: User:
Start: 09/30/05 End: - Due: -

1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement

Phase: N/A Priority: Normal
NCT ID: NCT02756650 Org: User:
Start: 06/23/16 End: 01/31/19 Due: 01/31/20

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT00622869 Org: User:
Start: 01/31/08 End: 04/30/12 Due: 04/30/13

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Phase: N/A Priority: Normal
NCT ID: NCT01317615 Org: User:
Start: 04/30/11 End: 03/31/15 Due: 03/31/16

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

Phase: N/A Priority: Normal
NCT ID: NCT00819585 Org: User:
Start: 12/31/08 End: 08/31/10 Due: 08/31/11

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00101803 Org: User:
Start: 01/31/05 End: 01/31/06 Due: 01/31/07

Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00383578 Org: User:
Start: 09/30/06 End: - Due: -

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT03930641 Org: User:
Start: 05/23/19 End: 07/02/19 Due: 07/02/20

Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients

Phase: N/A Priority: Normal
NCT ID: NCT01128335 Org: User:
Start: 04/30/10 End: 07/31/12 Due: 07/31/13

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00363051 Org: User:
Start: 06/30/06 End: 04/30/12 Due: 04/30/13

Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

Phase: N/A Priority: Normal
NCT ID: NCT01526889 Org: User:
Start: 12/20/12 End: 08/24/17 Due: 08/24/18